8-K: Catheter Precision Secures $250,000 Loan from Executive Chair Amidst Ongoing Funding Efforts

Catheter Precision, Inc. has obtained a $250,000 short-term loan from its Executive Chair and CEO, David A. Jenkins, to be repaid from potential proceeds of a future securities sale.

Summary

• Catheter Precision, Inc. received a $250,000 loan from an entity controlled by its Executive Chair and CEO, David A. Jenkins, on July 1, 2024.
• The loan is structured as an 8% short-term promissory note, due on August 30, 2024.
• This loan is in addition to previous loans from Mr. Jenkins totaling $650,000 in May and June 2024.
• The note's repayment is expected to come from the proceeds of a potential sale of securities under a registration statement filed with the SEC.
• The note includes standard default clauses, such as failure to pay, breach of warranties, or insolvency events, which could trigger immediate repayment.
• Mr. Jenkins and his affiliates have significant holdings in the company, including over 10% of common stock, preferred stock convertible into over 8 million common shares, stock options, and royalty rights on sales of the LockeT device.

Sentiment

Score: 3

Explanation: The document indicates a reliance on short-term, high-interest debt from a related party, suggesting financial strain and raising concerns about the company's long-term viability. The need for a capital raise is clear, but the success of that raise is not guaranteed.

Positives

• The company has secured additional funding through a short-term loan.
• The loan demonstrates the Executive Chair's confidence in the company's future.
• The loan is structured to be repaid from potential future capital raises, aligning incentives.

Negatives

• The company is relying on short-term debt financing.
• The loan has a high interest rate of 8%.
• The company's reliance on related-party loans may raise concerns about corporate governance.

Risks

• The company's ability to repay the loan is dependent on the successful sale of securities.
• Failure to secure funding through the sale of securities could lead to default on the loan.
• The company's financial situation appears to be precarious, requiring repeated short-term loans from related parties.
• The concentration of ownership and control with Mr. Jenkins and his affiliates could pose governance risks.

Future Outlook

The company expects to repay the loan from the proceeds of a potential sale of securities pursuant to its registration statement on Form S-1.

Management Comments

• The document does not contain direct quotes from management, but the loan agreement indicates the company's reliance on related-party funding.

Industry Context

The medical device industry often requires significant capital for research, development, and commercialization, making short-term loans a common financing method for companies in early stages. This loan suggests Catheter Precision is actively seeking funding to support its operations and growth.

Comparison to Industry Standards

• Many early-stage medical device companies rely on bridge financing, such as short-term loans, to fund operations while pursuing larger capital raises.
• The 8% interest rate is relatively high, which may reflect the perceived risk of the company and the short-term nature of the loan.
• Comparable companies often use convertible notes or equity financing to raise capital, which may be a future step for Catheter Precision.
• The reliance on related-party loans is not uncommon in early-stage companies, but it can raise concerns about conflicts of interest and corporate governance.

Related Party Transactions

• The $250,000 loan was provided by an entity controlled by David A. Jenkins, the Executive Chair and CEO of Catheter Precision, Inc.
• Mr. Jenkins and his affiliates beneficially own over 10% of the common stock of the Company, Series X Preferred convertible into over 8 million shares of Company common stock, stock options issued by the Company, and the rights to receive royalties on sales of our LockeT device equal to an aggregate 11.77% of net sales.

Stakeholder Impact

• Shareholders face increased risk due to the company's reliance on short-term debt.
• Creditors are exposed to the risk of default if the company cannot secure additional funding.
• Employees may be concerned about the company's financial stability.

Next Steps

• The company needs to successfully complete its securities sale to repay the loan.
• The company will need to continue to manage its cash flow and seek additional funding if the securities sale is not successful.

Key Dates

Keywords

promissory note, short-term loan, related party transaction, capital raise, debt financing, securities sale, Catheter Precision, David A. Jenkins